Toujeo Max Injection, Solution
NDC Package 0024-5871-01
Package Information
Toujeo Max (insulin glargine) injection is tOUJEO is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus. This formulation utilizes a injection, solution delivery system. Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0024-5871 and is authorized under FDA application BLA206538.
Identification & Billing
- RxCUI: 1604539 - insulin glargine 300 UNT/ML in 1.5 ML Pen Injector
- RxCUI: 1604539 - 1.5 ML insulin glargine 300 UNT/ML Pen Injector
- RxCUI: 1604539 - insulin glargine 300 UNT/ML per 1.5 ML Pen Injector
- RxCUI: 1604544 - Toujeo 300 UNT/ML in 1.5 ML Pen Injector
- RxCUI: 1604544 - 1.5 ML insulin glargine 300 UNT/ML Pen Injector [Toujeo]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0024 - Sanofi-aventis U.s. Llc
- 0024-5871 - Toujeo Max
- 0024-5871-01 - 1 SYRINGE in 1 CARTON / 3 mL in 1 SYRINGE
- 0024-5871 - Toujeo Max
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0024-5871). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0024-5871-01 identifies a specific commercial package of 1 syringe in 1 carton / 3 ml in 1 syringe of Toujeo Max, a human prescription drug labeled by Sanofi-aventis U.s. Llc. This injection, solution is formulated for subcutaneous use and contains insulin glargine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi-aventis U.s. Llc on February 15, 2015. The current certification is valid through December 31, 2026.
How is this Sanofi-aventis U.s. Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00024587101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
